Expression of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptors in Pancreatic Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

GONG Wei ¹

Organ Transplantation Center, Shandong Provincial Hospital, Shandong University, Jinan 250021, China;

Corresponding author：

Keywords：

Pancreatic neoplasmTumor necrosis factor-related apoptosis-inducing ligand receptorReverse transcription polymerase chain reaction

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【Abstract】　Objective　To investigate the expression and significance of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors in pancreatic cancer. Methods　Thirty-two samples of pancreatic cancer tissue were collected from year 2002 to 2004. All of them were verified by histopathology and there were 9 cases of well-differentiated, 12 of moderately differentiated, and 11 of poorly differentiated, in which 12 cases were in the stage of Ⅰor Ⅱand 20 in the stage of Ⅲ or Ⅳ according to the TNM staging method. Eighteen normal pancreatic tissues were used as control group. The expressions of TRAIL receptors (death receptor 4, death receptor 5, decoy receptor 4 and decoy receptor 5) mRNA were assayed by semi-quantitive reverse transcription polymerase chain reaction (RT-PCR) in the pancreatic cancer tissues and the normal pancreatic tissues. Results　The expressions of death receptor 4 (DR4) and death receptor 5 (DR5) were detected in all the pancreatic cancer tissues and the normal pancreatic tissues and the levels of DR4 and DR5 were significantly higher than those of the normal pancreatic tissues (P＜0.01). Decoy receptor 1 (DcR1) and decoy receptor 2 (DcR2) were also expressed in normal pancreatic tissues, whereas DcR1 and DcR2 were only expressed in 18 and 20 pancreatic cancer tissues, respectively. However, there were no significant difference of the expression of DcR1 and DcR2 between the pancreatic cancer tissues and the normal pancreatic tissues （P gt;0.05）. The expression level of DR5 in pancreatic cancer tissue was correlated with tumor differentiation and clinical stage, and the levels in stage Ⅲ and stage Ⅳwere significantly lower than those of stageⅠand stageⅡ(P＜0.05). The expressions of DR4, DcR1 and DcR2 were not correlated with tumor differentiation and clinical stage (P gt;0.05). Conclusion　①The expression of TRAIL receptors in pancreatic cancer tissues is prevalent, but the types of receptors expressed in different tissues were also different. High expression of death receptors may play an important role in TRAIL recptors regulated pancreatic cancer apoptosis. ②The expression of DR5 is correlated with the differentiation degree of pancreatic cancer cell and clinical stage of tumor. The expressions of DR4, DcR1 and DcR2 should not be considered as related indexes of differentiation degree or clinical stage of pancreatic cancer.

Citation： GONG Wei,LIU Jun,LIANG Fei,XU Shifeng,YANG Fenghui,ZHOU Xu,XU Yantian,YU Guangsheng,LI Guangbing.. Expression of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptors in Pancreatic Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2006, 13(5): 521-523下转530. doi: Copy

1.	Wiley SR, Schooley K, Smolak PJ, et al. Identification and ch-aracterization of a new member of the TNF family that induces apoptosis [Ｊ]. Immunity, 1995; 3(6)∶673.
2.	Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand [Ｊ]. J Clin Invest, 1999; 104(2)∶155.
3.	Liu W, Bodle E, Chen JY, et al. Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines [Ｊ]. Am J Respir Cell Mol Biol, 2001; 25(1)∶111.
4.	Satoh K, Kaneko K, Hirota M, et al. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer [Ｊ]. Pancreas, 2001; 23(3)∶251.
5.	Ozawa F, Friess H, Kleeff J, et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer [Ｊ]. Cancer Lett, 2001; 163(1)∶71.
6.	Ibrahim SM, Ringel J, Schmidt C, et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death [Ｊ]. Pancreas, 2001; 23(1)∶72.

1. 　Wiley SR, Schooley K, Smolak PJ, et al. Identification and ch-aracterization of a new member of the TNF family that induces apoptosis [Ｊ]. Immunity, 1995; 3(6)∶673.
2. 　Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand [Ｊ]. J Clin Invest, 1999; 104(2)∶155.
3. 　Liu W, Bodle E, Chen JY, et al. Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines [Ｊ]. Am J Respir Cell Mol Biol, 2001; 25(1)∶111.
4. 　Satoh K, Kaneko K, Hirota M, et al. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer [Ｊ]. Pancreas, 2001; 23(3)∶251.
5. 　Ozawa F, Friess H, Kleeff J, et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer [Ｊ]. Cancer Lett, 2001; 163(1)∶71.
6. 　Ibrahim SM, Ringel J, Schmidt C, et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death [Ｊ]. Pancreas, 2001; 23(1)∶72.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptors in Pancreatic Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content